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Emerging Monoclonal Antibodies 




Therapeutic measures designed to treat multiple myeloma (MM) have undergone 
a fundamental shift over the past two decades as a number of small molecules that 
attack this cancer by different mechanisms, including proteasome blockade, immu-
nomodulation, and histone deacetylase (HDAC) inhibition, have been introduced. 
The insertion of monoclonal antibodies (mAbs) into the mix began in 2015 with the 
U.S. Food and Drug Administration (FDA) approval of daratumumab and elotu-
zumab, which target CD38 and SLAMF7, respectively. In 2020, they were joined by 
another anti-CD38 mAb, isatuximab, and the bispecific antibody-drug conjugate 
(ADC) belantamab mafodotin, which targets the B-cell maturation antigen (BCMA). 
This review focuses on additional mAbs currently under clinical study for MM. These 
include several BCMAxCD3-directed bispecifics (AMG 420, AMG 701, REGN5458, 
REGN5459, teclistamab, and TNB-383B), the ADCs indatuximab ravtansine and 
STRO-001, and checkpoint inhibitors, although the future status of the latter is in a 
state of flux due to toxicity issues that arose in trials in which these drugs, especially 
PD-1 or PD-L1 blockers, were combined with immunomodulators.
Keywords: CD38, B-cell maturation antigen, daratumumab, elotuzumab, 
isatuximab, belantamab mafodotin, indatuximab ravtansine, STRO-001
1. Introduction
Multiple myeloma (MM), a malignancy of plasma cells, ranks second among 
all blood cancers in the U.S., representing about 1% of all diagnosed malignancies. 
In 2020, an estimated 32,270 individuals (54.3% male), the majority over age 65, 
will be diagnosed with the disease and approximately 12,830 will succumb to it 
[1]. Classical symptoms of active MM include hypercalcemia, renal insufficiency, 
anemia, and bone lesions (CRAB) and often are preceded by an asymptomatic stage 
referred to as monoclonal gammopathy of undetermined significance (MGUS). The 
risk of progression from MGUS to MM is about 1% per year [2] and may include 
another asymptomatic state known as smoldering myeloma [3]. Current guide-
lines for the diagnosis and treatment of MM have been published by the National 
Comprehensive Cancer Network (NCCN) [4]. Treatment modalities for MM 
have seen enormous advances since the beginning of the current century with the 
introduction of drugs working by different mechanisms, e.g., proteasome inhibition 
(bortezomib, carfilzomib, and ixazomib) and immunomodulation (lenalidomide 
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and pomalidomide), which were added to the long-established treatments based on 
alkylating agents (melphalan and cyclophosphamide) and corticosteroids (dexa-
methasone). These measures, together with autologous stem cell transplantation 
(ASCT), first introduced for MM in the 1990’s, have increased the five-year survival 
rate for the disease from 24% in the mid-1970s to 55% in the 2010–2016 period [5]. 
Furthermore, the relatively recent arrival on the scene of monoclonal antibodies 
(mAbs), beginning with the U.S. Food and Drug Administration (FDA) approval 
of daratumumab in 2015, has greatly expanded the therapeutic options available 
to treat MM. However, in spite of these advances, MM remains incurable as patient 
relapse and refractoriness to treatment continue as major issues. This review focuses 
on the contributions made by those mAbs currently approved for MM, as well as on 
those under investigation as potential future therapies for this disease.
2. mAbs targeting CD38
CD38 is a multifunctional 45 kDa type II transmembrane glycoprotein, lacking 
an internal signaling domain, that is expressed at high levels on both malignant and 
normal plasma cells and has attracted much interest as a target for drug develop-
ment in MM [6]. It also is found normally, but at lower levels, on the surfaces of 
T and B lymphocytes, natural killer (NK) cells, and monocytes. Among its several 
roles, CD38 acts as a receptor for CD31 (platelet endothelial cell adhesion molecule; 
PECAM-1) [7] and as a cyclic ADP ribose hydrolase, an ectoenzyme whose reaction 
products play an essential role in regulation of intracellular calcium levels [8].
Antibodies directed against CD38 kill myeloma cells by a number of possible 
mechanisms, chief among them being antibody-dependent cellular cytotoxicity 
(ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-
dependent cytotoxicity (CDC). Intracellular signal cascade disruption, the result of 
crosslinks formed between myeloma cell CD38 and Fcγ receptors on effector cells, 
may also play an important role in initiating apoptotic events in myeloma cells [9]. 
In addition, anti-CD38 antibodies have been shown to exhibit immunomodula-
tory effects that cause blockage of regulatory T- and B-cells and myeloid-derived 
suppressor cells [10].
Daratumumab (Darzalex®), a fully human IgG1κ mAb targeting CD38, 
initially was approved for the management of MM in patients who had relapsed 
following at least three prior therapies including an immunomodulator and a 
proteasome inhibitor [11]. Approval was supported by the results of two phase III 
trials - POLLUX (NCT02076009) and CASTOR (NCT02136134) - in which dara-
tumumab/dexamethasone was combined respectively with either lenalidomide 
[12] or bortezomib [13]. Further encouraging data from phase III trials, demon-
strating deeper and more sustained responses combined with good tolerability, 
soon enabled daratumumab/corticosteroid combinations with immunomodulators 
or proteasome inhibitors to assume an important role in even earlier courses of 
treatment [14, 15], as well as in newly diagnosed patients, whether ASCT-eligible 
[16] or -ineligible [17, 18]. Several network meta-analytic studies of random 
controlled trials covering a number of different settings, including in patients 
with newly diagnosed disease, have demonstrated the benefits of daratumumab-
containing regimens in MM therapy with respect to efficacy and safety [19]. 
Furthermore, several reports have indicated the efficacy of daratumumab mono-
therapy in patients who have failed earlier lines of anti-myeloma therapy [20], as 
well as in patients with smoldering MM [21]. Also, the FDA recently has approved 
a subcutaneous formulation of daratumumab plus hyaluronidase, which enables 
shorter infusion times without compromising safety or efficacy [22].
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Isatuximab (Sarclisa®, SAR650984) is a chimeric mouse-human IgG1κ CD38-
targeting mAb that was approved by the FDA in March 2020 for the treatment of 
relapsing and/or refractory MM (RRMM) in combination with pomalidomide and 
dexamethasone in patients who have received at least two prior therapies, including 
lenalidomide and a proteasome inhibitor [23]. Approval was predicated primarily 
on the results of the phase III ICARIA-MM trial (NCT02990338) in which addition 
of isatuximab to a pomalidomide/dexamethasone regimen resulted in a five month 
increase in median progression free survival (PFS), from 6.5 to 11.5 months [24]. 
Upper respiratory infections and diarrhea were the most frequently encountered 
adverse events noted in both groups. Although infusion reactions (mostly, grades 
1 and 2) were reported in 38% of patients in the isatuximab cohort, this reaction 
was not noted in any patients in the pomalidomide/dexamethasone group. An 
additional five phase III trials that include isatuximab/dexamethasone currently are 
in progress for: newly diagnosed MM (NDMM) (NCT03617731 and NCT03319667 
IMROZ - lenalidomide/bortezomib; NCT04483739 - lenalidomide/carfilzomib); 
RRMM (NCT03275285 IKEMA - carfilzomib); and high-risk smoldering MM 
(NCT04270409 - lenalidomide).
The mechanism of action of isatuximab exhibits some significant differences 
from that of daratumumab. For example, the former appears to work principally 
through ADCC with only minor contributions from CDC [25]. Also, unlike dara-
tumumab, crosslinking induced by isatuximab is not a prerequisite for initiation of 
target cell apoptosis [26]. Moreover, isatuximab is a much more potent inhibitor of 
ectoenzyme activity although the significance of this is unknown [27].
MOR202 (MOR03087, TJ202) is a fully humanized IgG1λ mAb that exhibited 
an objective response rate (ORR) of 29% in a phase II trial with dexamethasone in 
patients who had previously received four lines of therapy [28]. In addition, this 
drug has shown some promising efficacy when combined with immunomodulators 
[29, 30]. MOR202 also appears to offer the advantage of requiring reduced infu-
sion times and is associated with reduced infusion-related reactions compared to 
daratumumab or isatuximab, possibly due to its lack of dependency on CDC as 
a function of its activity. However, the drug’s sponsor, MorphoSys AG, recently 
decided to discontinue further development of MOR202 for MM. Two additional 
anti-CD38 mAbs from Takeda Oncology currently are in the early stages of clinical 
development for RRMM: TAK-573, an IgG4 antibody conjugated to an attenuated 
form of interferon α [31], and TAK-079, a fully humanized IgG1λ mAb [32].
3. mAbs targeting SLAMF7
A group of surface proteins belonging to the signaling lymphocytic activation 
molecule family (SLAMF) has elicited considerable interest in recent years due to the 
high expression of four family members (SLAMF2, 3, 6, and 7) on both normal plasma 
cells and those from MM patients at all stages of disease. No trials of SLAMF2-
targeting mAbs have been initiated and clinical studies of the SLAMF3 and SLAMF6 
mAbs SGN-CD48A and azintuxizumab vedotin (ABBV-838), respectively, both 
were halted early in phase I trials. On the other hand, SLAMF7 (CS1 or CD319) has 
emerged as the principal focus for new anti-myeloma mAb development in this 
group of targets with the introduction of elotuzumab (Empliciti®), a humanized 
IgG1κ mAb [33]. Preclinical studies revealed that the anti-myeloma activity of 
elotuzumab is the result of ADCC involving direct activation and engagement of 
NK cells [34]. FDA approval in 2015 of elotuzumab, which lacks activity as a single 
agent, was the result of the ELOQUENT-2 trial (NCT01239797) involving 646 
randomly assigned RRMM patients who received the mAb plus dexamethasone 
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with or without lenalidomide. The cohort receiving elotuzumab exhibited a PFS 
of 19.4 months and an ORR of 68% at one year and 41% at two years, compared 
to 14.9 months and 57% and 27% for the control [35]. These results were con-
firmed further by a subsequent four-year follow-up study [36]. Similar benefits 
of elotuzumab in RRMM were observed in combination with pomalidomide-
dexamethasone in the ELOQUENT-3 trial (NCT02654132) [37], which included 
patients refractory to both lenalidomide and a proteasome inhibitor and resulted 
in the 2018 FDA approval of this combination [38]. Favorable data also have been 
generated in a trial (NCT01478048) in which bortezomib-dexamethasone was 
included with elotuzumab [39].
4. BCMA-targeting antibody-drug complexes
The cytokines BAFF (B-cell activating factor) and APRIL (a proliferation-
inducing ligand) have received much attention in recent years for their roles in the 
pathophysiology of autoimmune diseases [40]. In addition, there is evidence that 
these two homologous members of the tumor necrosis factor (TNF) superfamily 
play roles in myeloma cell viability and proliferation [41]. Two other TNF family 
members - transmembrane activator and calcium modulator and cyclophilin ligand 
interactor (TACI) and B-cell maturation antigen (BCMA), located on the surface of 
myeloma cells, serve as ligands for both BAFF and APRIL [42]. While the respective 
BAFF and APRIL inhibitors, atacicept and tabalumab (LY2127399), as well as the 
anti-APRIL mAb BION-1301, showed poor efficacy in MM trials [43–45], BCMA 
has surfaced as a compelling target in anti-myeloma drug research [46].
BCMA normally plays a key role in B-cell differentiation into plasma cells 
[47]. Myeloma cells, whether from cell lines or patient samples, exhibit not only 
consistent and virtually exclusive elevation of BCMA levels and its mRNA during 
malignant transformation but also at similar levels during the various stages of 
MM from previously untreated to relapse [48]. A soluble form of BCMA (sBCMA), 
which results from the shedding of BCMA from the plasma cell surface by the 
action of γ-secretase, is an important factor that, by lowering the density of the 
target antigen while also providing a soluble decoy, potentially limits the efficacy of 
BCMA blockers in clinical development, accounting for the inclusion of γ-secretase 
inhibitors in a number of BCMA-targeted trials [49].
Removal of several of the fucosyl groups normally found in the N-linked 
biantennary complex oligosaccharides in the Fc region of IgG antibodies is a well-
established approach for enhancing ADCC through binding of FcγIIIa receptors 
on NK cells [50]. One such anti-BCMA mAb is the afucosylated antibody-drug 
conjugate (ADC) belantamab mafodotin (Blenrep®, GSK2857916), in which 
the antibody is coupled to the microtubule inhibitor monomethylauristatin F 
(MMAF) through a protease-resistant maleimidocaproyl linker. While the anti-
body component disrupts BAFF/APRIL myeloma cell signaling by binding to the 
BCMA receptor to induce ADCC, the MMAF component causes cell cycle arrest 
at the G2/M interface [51]. Belantamab mafodotin continues to be the subject 
of the DREAMM series of trials in RRMM patients. An early exploratory study 
(NCT02064387, DREAMM-1) found an ORR of 60% in 35 heavily pre-treated 
RRMM patients when the immunoconjugate was used as a single agent [52]. This 
encouraging response level dropped to 31% (30/97) in RRMM patients refrac-
tory to proteasome inhibitors, immunomodulators, and/or anti-CD38 therapy, 
who received the drug as monotherapy at 2.5 mg./Kg. in the ensuing phase II 
DREAMM-2 trial (NCT03525678) [53]. However, the efficacy level was considered 
comparable to that observed with other therapies for RRMM patients with similar 
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numbers of prior therapies. Analysis of adverse event data in the DREAMM-2 
trial concluded that belantamab mafodotin exhibits an acceptable safety profile 
with ocular toxicity, primarily in the form of keratopathy as the most commonly 
reported adverse event and attributable to the microtubule-inhibitor payload [54], 
presenting the greatest concern. Based on these data, in August, 2020, belan-
tamab mafodotin was approved by the FDA, under the provisions of accelerated 
review, as monotherapy for RRMM patients who have received at least four prior 
treatments that included an immunomodulator, a proteasome inhibitor, and an 
anti-CD38 monoclonal antibody [55]. In addition to these two milestone studies, a 
phase II trial (NCT04126200; DREAMM-5) has been initiated that includes belan-
tamab mafodotin monotherapy with two T-cell costimulatory agonist mAbs – the 
OX40-targeting GSK3174998 and the inducible co-stimulator (ICOS) GSK3359609, 
along with nirogacestat (PF-03084014), a γ-secretase inhibitor [56]. The ADC plus 
low-dose dexamethasone also is incorporated into four phase III investigations that 
include standard therapies such as: pomalidomide (NCT04162210; DREAMM-3, 
RRMM); bortezomib and daratumumab (NCT04246047; DREAMM-7, RRMM); 
pomalidomide and bortezomib (NCT04484623; DREAMM-8, RRMM); and 
lenalidomide and bortezomib (NCT04091126; DREAMM-9, NDMM) [57].
Another BCMA-targeted ADC that has elicited much interest for its anti-
myeloma action is MEDI2228, which is comprised of a fully human mAb attached 
to a minor-groove binding pyrrolobenzodiazepine (tesirine) payload via a 
protease-cleavable valine-alanine linker [58]. Release of the warhead following 
internalization of the immunoconjugate and trafficking to the lysosome results 
in DNA damage and subsequent apoptosis. Preclinical studies in mice revealed 
this agent’s potent anti-myeloma activity even when clinically significant levels of 
sBCMA were present [59]. Currently, MEDI2228 is the subject of a phase I clinical 
trial (NCT03489525) to determine appropriate dosing as monotherapy in RRMM 
patients; however, no results have been reported as yet. Another anti-BCMA ADC 
that has entered clinical studies for MM is AMG 224 (NCT02561962), comprised of 
a maytansine analog connected to a non-cleavable 4-(N-maleimidomethyl) cyclo-
hexane-1-carboxylate linker [60]. CC-99712 is yet another BCMA-targeted ADC 
(undisclosed composition) that recently entered a clinical trial (NCT04036461) for 
RRMM. Other anti-BCMA ADC mAbs that have demonstrated promise in preclini-
cal work but for which human studies have not yet begun include two proprietary 
products, referred to as BCMA-077 and BCMA-024 [61], and HDP-101, in which 
the conjugate is the potent RNA polymerase II subunit A (POLR2A) inhibitor 
α-amanitin [62].
5. T-cell-engaging bispecific antibodies
The T-cell-engaging bispecific antibody (T-BsAb) concept, originally developed 
by Nisonoff in 1961 [63], is based on the design of a dual-targeting antibody whereby 
one arm initially binds to the T-cell CD3 co-receptor complex while the other arm is 
subsequently directed to a tumor-associated antigen. The immunological synapse 
created between the two cells causes release of two cytolytic-initiating proteins: 
perforin, which causes formation of transmembrane pores in the malignant cell and 
granzyme B, which traverses the pores thus produced to initiate tumor cell apoptosis. 
The T-BsAb strategy differs from normal T-cell mediated cytotoxicity by removing 
requirements for costimulatory signals, formation of an antigen-major histocom-
patibility complex (MHC), and for ex vivo T-cell manipulation, thus permitting 
the possibility of “off-the-shelf” product manufacture. Furthermore, persistent 
T-cell activation enables polyclonal expansion of T memory cells. In addition, the 
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therapeutically relevant properties of constructs may be fine-tuned to optimization 
by altering biodistribution characteristics and the relative binding affinities of each 
arm for their respective targets [64].
Amgen’s proprietary BiTE® platform represents an innovative subclass of 
T-BsAb in which tandem single-chain variable fragments (scFvs) provide the cross-
link [65]. The first successful application of BiTE® technology was the CD3-CD19 
cross-linking construct blinatumomab (Blincyto®), which was approved by the 
FDA in 2014 for Philadelphia chromosome-negative B-cell precursor acute lympho-
cytic leukemia (B-cell ALL). Although a single trial (NCT03173430) of blinatu-
momab in RRMM patients had to be terminated because of “slow patient accrual”, 
the majority of myeloma-related work using BiTE® constructs have been based on 
recombinant antibodies designed to cross-link surface tumor-specific T-cell CD3ζ 
chains and targeted myeloma cell BCMA.
Initial results with the BCMAxCD3 BiTE® product AMG 420 (BI-836909), 
which was accorded fast-track status by the FDA in 2018, showed an ORR of 31% in 
42 RRMM patients, including seven of ten patients refractory to at least two lines 
of therapy who received the maximum tolerated dose of 400 μg/day. Infections and 
polyneuropathy were the most serious adverse events noted in this trial. Cytokine 
release syndrome (CRS; cytokine storm), predominantly grade 1, was observed in 
38% of patients in the study [66, 67]. Monotherapy with AMG 701, a related BiTE® 
construct with a longer serum half-life than AMG 420, currently is the focus of a 
phase I trial (NCT03287908) for RRMM. Data generated in a preclinical investiga-
tion suggests that future consideration of a trial of AMG 701 in combination with 
an immunomodulator may be warranted [68]. In addition, two other BCMAxCD3 
bispecific antibodies from Regeneron, REGN5458 (NCT03761108) and REGN5459 
(NCT04083534), are in phase I RRMM studies. Preliminary data on the first three 
patients treated with the former agent have been reported [69].
Following favorable safety results in a monkey model [70], two phase I RRMM 
clinical trials of the BCMAxCD3 bispecific teclistamab (JNJ-64007957) have been 
initiated. In addition to a dose-escalation study (NCT03145181), this agent has 
been incorporated into a trial (NCT04108195) that includes subcutaneous daratu-
mumab and talquetamab (JNJ-64407564), a CD3xGPRC5D bispecific construct. 
Another BCMAxCD3 formatted product under scrutiny for RRMM is PF-06863135 
(PF-3135) (NCT03269136), the result of hinge-mutation engineering of an IgG2a 
backbone [71]. CC-93269, a T-cell engager whose arms bind in a 2 + 1 arrangement, 
monovalently to CD3ε and bivalently to BCMA, is another member of this class in a 
myeloma-based trial (NCT03486067) [72].
TNB-383B, a BCMAxCD3 T-BsAb resulting from collaboration between Tenebio 
and Abbvie and designated as an orphan drug by the FDA, differs from other drugs 
in this class in that its structure consists of a single immunoglobulin light chain 
and two variable heavy chains. The product, which recently began a phase I trial 
for RRMM (NCT03933735), is noteworthy for its strong T-cell activation kinet-
ics and low affinity anti-CD3 arm, which results in reduced release of cytokines 
while retaining high cytotoxicity toward myeloma cells [73]. A number of other 
bispecific antibodies have exhibited promise for RRMM in preclinical work. These 
include TNB-381 M [74], FPA-151 [74], EM801 [48], and AP163 [75]. HPN217, 
developed by Harpoon Therapeutics, is a tri-specific antibody possessing three 
binding domains in a single chain – a C-terminal single-chain CD3ε T-cell receptor-
(TCR)-binding component, a human serum albumin-binding central domain, and 
an N-terminal BCMA-binding portion. This product, which is in a phase I/II trial 
for RRMM (NCT04184050), has an extended half-life compared to bispecific for-
mats, a property ascribed to its smaller size and flexibility [76]. Moreover, bispe-
cifics based on myeloma surface antigens other than BCMA have been developed 
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as alternative CD3 epitope binding partners. In addition to the aforementioned 
talquetamab (NCT03399799) [77], these include the CD3xCD38 construct found 
in GBR 1342 (NCT03309111) [78] and the CD3xFcRH5 design incorporated into 
BFCR4350A (NCT03275103) [79].
In addition to the BCMAxCD3 bispecific formats noted above, creation of 
BCMA-targeted constructs directed to receptors on NK cells has been described. 
Like cytotoxic T-cells, NK cells are known to mediate cytotoxicity through a variety 
of mechanisms, including granzyme-perforin release and through expression of 
various apoptosis-inducing ligands [80]. A tri-specific product that binds both 
BCMA and CD200 on myeloma cells to CD16A on NK cells represents one such drug 
[81]. Similarly, CTX-4419, which binds BCMA to both NK cell CD16A and p30, 
has shown initial promise in preclinical models although CD16A binding does not 
appear to be a requirement for the anti-myeloma activity of this product [82]. Other 
BCMA-NK cell-engaging antibodies, such as CTX-8573 [83] and AFM26 [84], also 
have shown some potential as RRMM therapies.
6. Immune checkpoint inhibitors
Over the past decade, immune checkpoint blockade has emerged as a principal 
strategy for new antitumor drug development. This immunotherapeutic approach 
is based on identification of biomarkers and their cognate ligands that enable the 
body’s immune system to overcome the capacity of tumor cells to evade immune 
surveillance and elimination, as well as on the design of mAbs to block these 
interactions. In its most successful application to date, discoveries made concerning 
the roles played in this process by cytotoxic T-lymphocyte–associated protein-4 
(CTLA-4), the first member of this class to serve as a clinical target, and the 
programmed death (PD) receptor, have given momentum to this innovative line of 
attack on a variety of tumor types [85].
Costimulatory signals resulting from interaction of CD28 on the surface of 
T-cells with its CD80 (B7–1) ligand on antigen-presenting cells play an important 
role in activating T-cells. CTLA-4, expressed on the T-cell plasma membrane, 
competes with CD80-CD28 binding to downregulate T-cell activation and thus 
represents an important mechanism that suppresses immune responses and, as 
a consequence, enables tumor cells to evade detection. CTLA-4-directed mAbs, 
by competing with the CD80-CD28 interaction, enhance the ability of T-cells to 
generate an antitumor response. This strategic approach was successfully applied to 
the immunotherapy of advanced melanoma by the anti-CTLA-4 mAb ipilimumab, 
which was approved by the FDA in 2011 and has been extended since to include a 
number of other solid tumors [86]. However, the drug has shown less than impres-
sive results in hematologic cancers, such as acute myeloid leukemia [87]. One trial 
(NCT02681302) of ipilimumab combined with nivolumab that included both 
lymphoma and MM patients is currently active but so far only preliminary efficacy 
and toxicity data have been reported [88].
Binding of PD-1, expressed on the surface of T-cells, to PD-L1 or PD-L2 on 
tumor cells inhibits cytotoxic T lymphocyte proliferation and cytokine secretion 
while also causing an increase in the T regulatory cell population. These combined 
effects produce immune tolerance, enabling unrestrained tumor cell growth and 
survival [89]. Since 2014, the FDA has approved three PD-1 inhibitors – pem-
brolizumab (Keytruda®), nivolumab (Opdivo®), and cemiplimab (Libtayo®) 
and three PD-L1 blockers – avelumab (Bavencio®), durvalumab (Imfinzi®), and 
atezolizumab (Tecentriq®). Pembrolizumab, the first to be approved and the 
most versatile member of the checkpoint blocker group, has been approved for 
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17 different indications, many as front-line therapy for solid tumors ranging from 
melanoma to small-cell lung cancer to metastatic Merkel cell carcinoma [90]. 
In 2017, the FDA in an unprecedented move approved pembrolizumab for the 
treatment of solid tumors having a microsatellite instability (mismatched repair 
Trial ID [reference] N Trial title
PD-1 Inhibitors
NCT03848845 [102] 40 A phase I/II single arm open-label study to explore safety and 
clinical activity of GSK2857916 administered in combination with 
pembrolizumab in subjects with relapsed/refractory multiple 
myeloma (DREAMM 4)
NCT03506360 41 Phase II trial of pembrolizumab, ixazomib, and dexamethasone 
for relapsed multiple myeloma
NCT04361851 33 Phase II study of daratumumab-pembrolizumab for multiple 
myeloma patients with ≥ three prior lines of therapy
NCT03168438 [103] 20 NY-ESO-1ᶜ259T alone and in combination with pembrolizumab for 
multiple myeloma
NCT03782064 25 A phase II trial of vaccination with dendritic cell (DC)/myeloma 
fusions in combination with nivolumab in patients with relapsed 
multiple myeloma
NCT03292263 [104] 30 Autologous stem cell transplantation with nivolumab in patients 
with multiple myeloma
NCT04119336 50 A phase II study of nivolumab in combination with ixazomib, 
cyclophosphamide, and dexamethasone in relapsed and refractory 
multiple myeloma
NCT03194867 109 A phase I/II study to evaluate safety, pharmacokinetics and 
efficacy of isatuximab in combination with cemiplimab in patients 
with relapsed/refractory multiple myeloma
NCT03111992 26 Phase I/Ib, multi-center, open-label, study of single agent CJM112 
(anti-IL17A mAb), and spartalizumab (PDR001) in combination 
with LCL161 (SMAC mimetic) or CJM112 in patients with 
relapsed and/or refractory multiple myeloma
PD-L1 Inhibitors
NCT02431208  
[105, 106] Trial Start: 
7/22/15
300 A phase Ib study of the safety and pharmacokinetics 
of atezolizumab alone or in combination with an 
immunomodulatory drug and/or daratumumab in patients with 
multiple myeloma (relapsed/ refractory and post-autologous stem 
cell transplantation)
NCT03910439 30 A phase II pilot study of avelumab in combination with 
hypofractionated radiotherapy in patients with relapsed refractory 
multiple myeloma
CD47 Inhibitors
NCT03530683 156 A phase Ia/Ib dose escalation and expansion trial of TTI-622 
in patients with advanced relapsed or refractory lymphoma or 
myeloma
LAG-3 and TIGIT Inhibitors
NCT04150965 104 A phase I/II assessment of combination immuno-oncology 
drugs elotuzumab, anti-LAG-3 (BMS-986016) and anti-TIGIT 
(BMS-986207)
Trial start date on or after July 1, 2017, unless otherwise noted.
Table 1. 
Selected active trials of checkpoint inhibitors in MM.
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deficiency). Known as a tissue agnostic approach to cancer diagnosis and treatment, 
this marked the first drug approval based on a specific biomarker instead of on the 
tissue or organ of origin [91].
In terms of hematologic malignancies, pembrolizumab has been approved for 
treatment of Hodgkin’s lymphoma while both pembrolizumab and nivolumab have 
been approved for primary mediastinal large B-cell lymphoma (PMBCL). While 
studies of checkpoint inhibitors in both chronic and acute leukemias generally have 
been disappointing [87], work in the area of MM has shown some degree of efficacy 
but major issues concerning toxicity have arisen. Following favorable results in early 
phase trials [92, 93], pembrolizumab/dexamethasone was included in two phase 
III trials with and without the immunomodulators lenalidomide (NCT02579863—
KEYNOTE-185; NDMM) and pomalidomide (NCT02576977—KEYNOTE-183; 
RRMM). However, in July 2017, the FDA placed clinical holds on both trials due 
to the higher risk of death in the cohorts receiving the PD-1 blocker [94]. This 
suspension soon was expanded to include partial or full holds on all myeloma trials 
using combinations of immunomodulators and checkpoint inhibitors, an action 
that later was reversed in the case of three myeloma trials that employed nivolumab 
(NCT03023527, NCT01592370, and NCT02612779); however, no data have been 
forthcoming for these resumed studies. At this point, any future role that check-
point inhibitor-immunomodulator combinations may play in MM therapy is very 
much in a state of flux [95]. Other checkpoints that may serve as targets for MM but 
for which only limited preclinical or clinical studies are currently available include 
killer-cell immunoglobulin-like receptors (KIR) [96], CD47 [97], LAG3 [98], TIGIT 
[99, 100], and TIM-3 [101]. Table 1 contains a partial list of checkpoint inhibitors 
currently in clinical trials for MM.
7. Additional mAbs and their targets
CD138 (syndecan-1), which is overexpressed in MM [107], is the target of 
indatuximab ravtansine (BT-062), an ADC whose anti-CD138 mAb is linked to a 
cytotoxic microtubule destabilizing maytansinoid. This agent has been studied in 
RRMM both in combination with immunomodulators (NCT01638936) and as a 
single agent (NCT01001442 and NCT00723359). The 34 patients (median 5 prior 
therapies) in the monotherapy study who received a multi-dose regimen showed 
a median PFS of three months and median overall survival (OS) of 26.7 months 
while diarrhea and fatigue were the most commonly reported adverse events [108]. 
In addition, an anti-CD138 mAb, known as mAb 1610, has shown some potential 
anti-myeloma promise in a preclinical study [109].
CD74 plays a key role as a chaperone, enabling the proper folding and traf-
ficking of MHC Class II proteins in antigen-presenting cells. In addition, this 
type II transmembrane protein activates the NFκB signaling pathway following 
the binding of its intracellular domain to macrophage migration inhibitory factor 
(MIF) and translocation to the nucleus where it induces proliferation and sur-
vival, especially in B-cells. Elevated expression of CD74 in B cell malignancies, 
such as non-Hodgkin’s lymphomas and MM, has made this an attractive target 
for these types of cancer [110]. STRO-001, which has received Orphan Drug 
status from the FDA, is an anti-CD74 ADC in which an aglycosylated human 
IgG1 antibody is conjugated to a maytansinoid linker-warhead. A phase I trial 
(NCT03424603) of STRO-001 in B-cell malignancies, including MM, recently 
was initiated [111]. Two other CD74-targeting agents, milatuzumab and its 
doxorubicin-linked ADC, that had been under study in MM, both have been 
dropped from further consideration.
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Another conjugate linked to a maytansine derivative, the anti-CD56 ADC 
lorvotuzumab mertansine (IMGN901; BB-10901), had been the focus of a phase 
I trial in CD56-positive RRMM patients (NCT00346255) but insufficient efficacy 
and dose-related toxicity reportedly led to discontinuation of further studies of this 
agent [112, 113]. Other mAbs that have been dropped from further consideration 
in MM following demonstration of only modest efficacy and/or unacceptable 
toxicity in trials include the following (target in parentheses): dacetuzumab and 
lucatumumab (CD40); F50067 (CXCR-4); AVE1642 and figitumumab (IGF-R1); 
IPH 2101 (KIR); PAT-SM6 (GRP-78); BI 505 (intercellular adhesion molecule-1, 
ICAM-1), and siltuximab (IL-6).
8. Conclusion
The number of therapeutic options available to treat MM has witnessed a 
remarkable upsurge since the turn of the current century. The advent of proteasome 
inhibitors and immunomodulators, in addition to other small molecules working by 
additional mechanisms, such as histone deacetylase (HDAC) blockade and nuclear 
export inhibition, has resulted in a major alteration in the clinical approach to the 
disease. Over the past half-decade, the introduction of mAbs into the fight against 
this malignancy has further shifted the landscape of how this disease is treated 
both in newly diagnosed patients and in the relapsed/refractory setting. Chief 
among these newer entries are daratumumab and elotuzumab, and more recently 
the anti-CD38 mAb isatuximab and the bispecific antibody belantamab mafodotin. 
Although employment of mAbs in combination with small molecule agents, such 
as bortezomib and lenalidomide, has been of immense value in extending patients’ 
ability to achieve deep and durable remissions, relapse and refractoriness to therapy 
remain as major obstacles to attainment of a cure. Work on checkpoint inhibitors, 
which have been employed successfully in several tumor types and had shown early 
promise in MM, continues to move forward in clinical studies of MM, although 
tempered by recent setbacks stemming from toxicity concerns when used in combi-
nation with immunomodulators.
It is evident that future advances in treating MM will be dependent on  
gaining even deeper insight into the transformative molecular events leading to the 
disease. As new biomarkers that drive this unrelenting malignancy are identified, 
design and discovery of innovative target-based therapeutic approaches that will 
find their way into clinical practice will be established. The attainments already 
realized by the advent of mAbs, particularly daratumumab, in recent years offers 
some prospect for even greater success in the application of mAbs in MM over the 
coming decade.
11
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